Long-term safety and efficacy of budesonide in the treatment of ulcerative colitis

Clinical and Experimental Gastroenterology

Volumn 7, Issue 1, 2014, Pages 39-46

  Iborra, Marisa ^a   Álvarez Sotomayor, Diego ^a   Nos, Pilar ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Budesonide; Crohn's disease; Safety; Ulcerative colitis

Indexed keywords

EID: 84893546852     PISSN: None     EISSN: 11787023     Source Type: Journal    
DOI: 10.2147/CEG.S34715     Document Type: Review

References (44)

1. Dignass A, Lindsay JO, Sturm A, etal. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012;6(10):991-1030.
2. Nunes T, Barreiro-de Acosta M, Marin-Jimenez I, Nos P, Sans M. Oral locally active steroids in inflammatory bowel disease. J Crohns Colitis. 2013;7(3):183-191.
3. O'Donnell S, O'Morain CA. Therapeutic benefits of budesonide in gastroenterology. Ther Adv Chronic Dis. 2010;1(4):177-186.
4. Gross V. Oral pH-modified release budesonide for treatment of inflammatory bowel disease, collagenous and lymphocytic colitis. Expert Opin Pharmacother. 2008;9(7):1257-1265.
5. Dignass A, Van Assche G, Lindsay JO, etal; European Crohn's and Colitis Organisation (ECCO). The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis. 2010;4(1):28-62.
6. Hanauer S, Sandborn WJ, Persson A, Persson T. Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial. Aliment Pharmacol Ther. 2005;21(4):363-371.
7. Sandborn WJ, Lofberg R, Feagan BG, Hanauer SB, Campieri M, Greenberg GR. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol. 2005;100(8):1780-1787.
8. Sherlock ME, Seow CH, Steinhart AH, Griffiths AM. Oral budesonide for induction of remission in ulcerative colitis [review]. Cochrane Database Syst Rev. 2010(10):CD007698.
9. Sandborn WJ, Travis S, Moro L, etal. Once-daily budesonide MMX(R) extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology. 2012;143(5):1218-1226. e1-e2.
10. Munch A, Aust D, Bohr J, etal; European Microscopic Colitis Group (EMCG). Microscopic colitis: Current status, present and future challenges: statements of the European Microscopic Colitis Group. J Crohns Colitis. 2012;6(9):932-945.
11. Gentile NM, Abdalla AA, Khanna S, etal. Outcomes of patients with microscopic colitis treated with corticosteroids: a population-based study. Am J Gastroenterol. 2013;108(2):256-259.
12. Lofberg R, Danielsson A, Salde L. Oral budesonide in active Crohn's disease. Aliment Pharmacol Ther. 1993;7(6):611-616.
13. Marin-Jimenez I, Pena AS. Budesonide for ulcerative colitis. Rev Esp Enferm Dig. 2006;98(5):362-373. Spanish.
14. Patel NV, Patel JK, Shah SH, Patel JN. Central composite design for the formulation and optimization of a multi-unit potential colonic drug delivery system of budesonide for ulcerative colitis. Pharmazie. 2011;66(2):124-129.
15. Brunner M, Ziegler S, Di Stefano AF, etal. Gastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulation. Br J Clin Pharmacol. 2006;61(1):31-38.
16. Fiorino G, Fries W, De La Rue SA, Malesci AC, Repici A, Danese S. New drug delivery systems in inflammatory bowel disease: MMX and tailored delivery to the gut. Curr Med Chem. 2010;17(17):1851-1857.
17. De Cassan C, Fiorino G, Danese S. Second-generation corticosteroids for the treatment of Crohn's disease and ulcerative colitis: more effective and less side effects? Dig Dis. 2012;30(4):368-375.
18. D'Haens GR, Kovacs A, Vergauwe P, etal. Clinical trial: Preliminary efficacy and safety study of a new Budesonide-MMX(R) 9mg extended-release tablets in patients with active left-sided ulcerative colitis. J Crohns Colitis. 2010;4(2):153-160.
19. Barnes PJ. Molecular mechanisms and cellular effects of glucocorticosteroids. Immunol Allergy Clin North Am. 2005;25(3): 451-468.
20. Silverman J, Otley A. Budesonide in the treatment of inflammatory bowel disease. Expert Rev Clin Immunol. 2011;7(4):419-428.
21. Ardizzone S, Bianchi Porro G. Comparative tolerability of therapies for ulcerative colitis. Drug Saf. 2002;25(8):561-582.
22. Lichtenstein GR, Bengtsson B, Hapten-White L, Rutgeerts P. Oral budesonide for maintenance of remission of Crohn's disease: a pooled safety analysis. Aliment Pharmacol Ther. 2009;29(6): 643-653.
23. D'Haens G, Verstraete A, Cheyns K, Aerden I, Bouillon R, Rutgeerts P. Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn's disease. Aliment Pharmacol Ther. 1998;12(5): 419-424.
24. Schoon EJ, Bollani S, Mills PR, etal; Matrix Study Group. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease. Clin Gastroenterol Hepatol. 2005;3(2):113-121.
25. Beaulieu DB, Ananthakrishnan AN, Issa M, etal. Budesonide induction and maintenance therapy for Crohn's disease during pregnancy. Inflamm Bowel Dis. 2009;15(1):25-28.
26. Piette V, Daures JP, Demoly P. Treating allergic rhinitis in pregnancy. Curr Allergy Asthma Rep. 2006;6(3):232-238.
27. Norjavaara E, de Verdier MG. Normal pregnancy outcomes in a population-based study including 2,968 pregnant women exposed to budesonide. J Allergy Clin Immunol. 2003;111(4):736-742.
28. Lundin PD, Edsbacker S, Bergstrand M, etal. Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn's disease. Aliment Pharmacol Ther. 2003;17(1): 85-92.
29. Levine A, Weizman Z, Broide E, etal; Israeli Pediatric Gastroenterology Association Budesonide Study Group. A comparison of budesonide and prednisone for the treatment of active pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2003;36(2):248-252.
30. Levine A, Kori M, Dinari G, etal; Israeli Pediatric Budesonide Study Group. Comparison of two dosing methods for induction of response and remission with oral budesonide in active pediatric Crohn's disease: a randomized placebo-controlled trial. Inflamm Bowel Dis. 2009;15(7): 1055-1061.
31. Escher JC; European Collaborative Research Group on Budesonide in Paediatric IBD. Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial. Eur J Gastroenterol Hepatol. 2004;16(1): 47-54.
32. Lofberg R, Danielsson A, Suhr O, etal. Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. Gastroenterology. 1996;110(6):1713-1718.
33. Gross V, Bunganic I, Mikhailova TL, etal. Efficacy and tolerability of a once daily treatment with budesonide capsules versus mesalamine granules for the treatment of active ulcerative colitis: a randomized, double-blind, double-dummy, multicenter study. Gastroenterology. 2009;136(5 Suppl 1):A-15.
34. Gross V, Bunganic I, Belousova EA, etal; International BUC-57 Study Group. 3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial. J Crohns Colitis. 2011;5(2): 129-138.
35. Keller R, Stoll R, Foerster EC, Gutsche N, Domschke W. Oral budesonide therapy for steroid-dependent ulcerative colitis: a pilot trial. Aliment Pharmacol Ther. 1997;11(6):1047-1052.
36. Kolkman JJ, Mollmann HW, Mollmann AC, etal. Evaluation of oral budesonide in the treatment of active distal ulcerative colitis. Drugs Today (Barc). 2004;40(7):589-601.
37. Chopra A, Pardi DS, Loftus EV Jr, etal. Budesonide in the treatment of inflammatory bowel disease: the first year of experience in clinical practice. Inflamm Bowel Dis. 2006;12(1):29-32.
38. Sandborn WJ, Danese S, Ballard ED, etal. Efficacy of budesonide MMx® 6 mg QD for the maintenance of remission in patients with ulcerative colitis: results from a phase III, 12month safety and extended use study. Gastroenterology. 2012;142(5 Suppl 1):S-564.
39. Gionchetti P, Rizzello F, Poggioli G, etal. Oral budesonide in the treatment of chronic refractory pouchitis. Aliment Pharmacol Ther. 2007;25(10):1231-1236.
40. Cabriada Nuno JL, Hernandez Martin A, Bernal Martinez A, Zabalza Estevez I. Oral budesonide in the treatment of chronic refractory pouchitis. Gastroenterol Hepatol. 2008;31(8):485-489. Spanish.
41. Budesonide enema in distal ulcerative colitis. A randomized dose-response trial with prednisolone enema as positive control. The Danish Budesonide Study Group. Scand J Gastroenterol. 1991;26(12): 1225-1230.
42. Gomollon F, Hinojosa J, Nos P. Budesonide and inflammatory bowel disease. Gastroenterol Hepatol. 1999;22(10):525-532. Spanish.
43. Lemann M, Galian A, Rutgeerts P, etal. Comparison of budesonide and 5-aminosalicylic acid enemas in active distal ulcerative colitis. Aliment Pharmacol Ther. 1995;9(5):557-562.
44. Hartmann F, Stein J; BudMesa-Study Group. Clinical trial: controlled, open, randomized multicentre study comparing the effects of treatment on quality of life, safety and efficacy of budesonide or mesalazine enemas in active left-sided ulcerative colitis. Aliment Pharmacol Ther. 2010;32(3):368-376.